The pair will develop drug-digital therapeutic combinations as a singular product, thus sidestepping reimbursement hurdles linked to individually approved digital therapies.

Intellia Therapeutics Inc. said its gene-editing treatment for a rare swelling disorder met its goal in a late-stage trial, ...

By Michael Erman NEW YORK, April 27 (Reuters) - Johnson & Johnson is using artificial intelligence to slash by half the time ...

One CEO said people should be using AI to understand their health much more than they already do.

Isomorphic Labs president Max Jaderberg said at WIRED Health in London that the startup has built a “broad and exciting ...

By Amina Niasse NEW YORK, April 27 (Reuters) - Humana announced on Monday it will launch a pharmacy partnership with Mark ...

A stick-on gel for plants could one day offer a simple, safe and targeted way to treat diseases and pests. Engineers at the ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the 'Company” or 'Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

The United Nations Office on Drugs and Crime (UNODC) said Nigeria will no longer be a permissive ground for international ...

Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence ...

In separate clinical trials, two treatments showed promise that they could help patients with one of the most dire diagnoses ...

During one arrest, footage shows a Metropolitan Police officer chasing and knocking down a suspect on a motorbike with an L ...